MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE MAY 31, 2018 MEETING

ATTENDANCE SFY2018

DUR Board Members:	July 2017	Nov 2017	Mar 2018	May 2018
Allison Bell, PharmD	✓	✓	NA	NA
Rhonda Dunaway, RPh		✓	✓	✓
Craig Escudé, MD	✓		✓	NA
Juanice Glaze, RPh		✓	✓	✓
Alice Messer, DNP, FNP-BC	✓	✓	✓	✓
Ray Montalvo, MD	NA	✓	✓	✓
Holly Moore, PharmD	NA		✓	
Janet Ricks, DO		✓	✓	
Sue Simmons, MD		✓		✓
Dennis Smith, RPh	NA		✓	✓
James Taylor, PharmD (Chair)		✓	✓	✓
Pearl Wales, PharmD	✓	✓		✓
TOTAL PRESENT	**4***	**9**	**9****	**8*****

**Only 8 members were active due to new appointments to DUR Board not being approved by Governor prior to meeting.*
*** Only 11 members were active due to resignation resulting from move and replacement not yet approved by Governor.*
**** Only 10 members were active due to resignations resulting from move and replacements not yet approved by Governor.*

Also Present:

Division of Medicaid (DOM) Staff:
Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Drew Snyder, JD, Executive Director; Anita Smith, RN; Shereen Wilson, RN, Clinical Support Services; Darlene Touchet, RN; Sue Reno, RN, Program Integrity

University of Mississippi School of Pharmacy - MS-DUR Staff:
Ben Banahan, PhD, MS-DUR Project Director; Eric Pittman, PharmD, MS-DUR Clinical Director; Anna Crider, University of Mississippi School of Pharmacy Student; Mariah Cole, University of Mississippi School of Pharmacy Student

Conduent Staff:
Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project; Lew Anne Snow, RN, BSN, Pharmacy Services Sr. Analyst, Mississippi Medicaid Project; Felecia Lobrano, RN, Professional Services Sr. Analyst

Change Healthcare Staff:
Shannon Hardwick, RPh, CPC Pharmacist; Cheryl Rogers, PharmD, Mississippi PA Pharmacist; Paige Clayton, PharmD, On-Site Clinical Pharmacist

Coordinated Care Organizations:
Heather Odem, PharmD, United Healthcare Community & State, Director of Pharmacy- Mississippi; Conor Smith, MS, RPh, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President, Pharmacy Operations, Magnolia Health

Visitors:
Phil Hecht, Abbvie; Kent Ulveling, Abbvie; Dan Doyle, Trividia; Leigh Faircloth, Johnson and Johnson; Steven Zona, Johnson and Johnson; Tim Hambacher, Otsuka; Jason Swartz, Otsuka; Judy Clark, Consultant; Angela Brown, BI; David Seel, BI; Jay Breyner, BI; Steve Curry, ALK; Darlene Bitel, Shire; Doug Welch, Merck; Beverly Bryant, MD, UMMC; Lauren Bloodworth, PharmD, University of Mississippi School of Pharmacy

Call to Order:
Dr. Taylor, Chair, called the meeting to order at 2:02pm and welcomed everyone. Dr. Taylor and Dr. Noble, on behalf of Medicaid, recognized Dr. Janet Ricks, Dr. Pearl Wales and Dr. Sue Simmons, whose terms are expiring June 2018, and thanked them for their service and contributions to the DUR Board.

Old Business:
Dr. Taylor moved to approve the minutes from the March 2018 DUR Board Meeting, seconded by Dr. Montalvo and unanimously approved by the DUR Board.

Resource Utilization Review:
Dr. Pittman informed the board that encounter data for Magnolia was incomplete for February 2018 at the time the report was run. Although this should not impact any of the resource utilization ranks, it does impact the following: dollar amounts paid, number of claims, and number of beneficiaries for the month of February. In reference to top categories by volume or dollars, no unexpected shifts were noted for this time of year. Dr. Montalvo asked about trends in regards to narcotics and stimulants. Dr. Banahan indicated a trend analysis was planned for the next DUR Board Meeting.

Pharmacy Program Update:
Dr. Noble updated the Board on the progress of some opioid initiatives stating that DOM is trying to be in alignment with new regulations under development from the State Medical Licensure Board regarding opioid prescribing. She informed the board that DOM is moving forward on the clinical edits to implement the Board's recommendations for concomitant use of opioids and benzodiazepines. Dr. Noble asked Ms. Reno, DOM Program Integrity, to provide an update on activities in their division. Dr. Noble also informed the Board that the Federal Fiscal Year 2017 Medicaid Drug Utilization Review Annual Report due to CMS by June 30, 2018 is being finalized. She briefed the Board on pharmacy related changes in the Medicaid Technical Bill that was recently passed by the legislature and signed by the governor. Mrs. McCorkle gave an update on NADAC reimbursement reprocessing with an expected completion at the end of July 2018.

N**EW BUSINESS**

Feedback and Discussion from the Board
Dr. Pittman asked if any board members had items they wanted to call to the attention of DOM or MS-DUR. Dr. Noble updated the Board on the status of some recent DUR Board decisions. Changes related to the stimulant edits approved by the Board are tentatively scheduled for an October 2018 implementation and the Proton Pump Inhibitor edits are tentatively scheduled for January 2019 implementation. Dr. Montalvo asked if DOM could look into access to the PCSK9 inhibitor drug class. Dr. Noble informed the Board that DOM has criteria in place for this class, but requested Dr. Montalvo review this criteria. Mr. Smith inquired about gabapentin utilization. Board members discussed recent DUR action on this class and the potential for the Mississippi Board of Pharmacy to move gabapentin to a controlled substance.

Election of Officer
Dr. Messer nominated Dr. Montalvo as Co-Chair, seconded by Dr. Simmons and passed unanimously.

Update on MS-DUR Educational Interventions
Dr. Pittman provided an overview of educational mailings that were conducted during the last quarter.

Research Reports:
Stimulants and Associated Diagnoses for Clinical Edit
At the March 2018 DUR Board meeting a recommendation was approved to implement diagnosis edits for stimulants in both children and adults. Dr. Pittman presented an overview of follow-up analyses conducted by MS-DUR regarding the presence of approved diagnoses for past stimulant prescriptions. Following a robust discussion, the following recommendations were made by the DUR Board:

1. DOM should implement an electronic prior authorization procedure requiring the presence of at least one of the listed FDA approved or compendia supported diagnoses for each stimulant product. This diagnosis can be present in the medical claims paid within 24 months of the prescription fill or written on the prescription by the provider and submitted by the pharmacist with the prescription claim. (NOTE: The DUR Board has already approved such an edit, this is a confirmation of the approved indications that will be listed for each product.)

Dr. Taylor moved to accept recommendation number 1 as approved at the March 2018 DUR Board meeting. The motion was seconded by Dr. Montalvo and approved unanimously.

Prior to Implementation of the Edit:

2. MS-DUR will initiate an educational mailing to inform providers about the diagnosis requirement and will work with the Mississippi Chapter of the American Academy of Pediatrics, Mississippi Psychiatric Association, Mississippi State Medical Association and other state professional medical, nursing and pharmacy associations to electronically disseminate information about the upcoming edit. DOM should seek to have these associations' endorsement of this notice if permissible.

Dr. Wales moved to approve recommendation number 2. The motion was seconded by Mr. Smith and approved unanimously.

3. DOM will include a notice about the upcoming edit in the upcoming Provider Bulletin(s).

Ms. Dunaway moved to approve recommendation number 3. The motion was seconded by Dr. Montalvo and approved unanimously.

Pharmacotherapeutic Management of Sickle Cell Disease (SCD)
Dr. Pittman provided a review of SCD treatment and the recent approval of Endari for treatment of SCD related pain. He reviewed the MS-DUR analysis on utilization of hydroxyurea and Endari. The Board indicated a desire to have a hematologist present to the board before taking action.

Motion to table action until after Board can have a presentation on SCD treatment was made by Dr. Messer, seconded by Dr. Montalvo and approved unanimously.

Makena Utilization in Mississippi Medicaid
MS-DUR was asked to examine utilization of Makena in response to prescriber feedback to DOM regarding difficulties in obtaining the product. Dr. Pittman provided a background on utilization of Makena and the findings from the MS-DUR analysis and interviews. After a robust discussion, the following recommendations were proposed by the DUR Board:

1. MS-DUR should share results with other health service office directors within Mississippi Medicaid who are examining access to Makena.
2. MS-DUR should assist in coordinating educational initiatives for providers and beneficiaries. Provider education should highlight benefits of prescribing Makena, outline the ordering process and stress the need for patient education regarding the confirmation phone call from the manufacturer that must be completed prior to initiation of treatment.
3. MS-DUR should work with AMAG Pharmaceuticals and other specialty pharmacies to coordinate additional education. The benefits of Makena and the ordering process for prescribers, especially those prescribers who may not be as familiar with the process, should also be addressed.

Mr. Smith made a motion to approve the recommendations, seconded by Dr. Taylor, and approved unanimously.

Palivizumab (Synagis) Utilization Update: 2015-16 through 2017-18 Seasons
Dr. Banahan gave a background on Synagis and the shift to using the CDC National Respiratory and Enteric Virus Surveillance System to determine the appropriate seasons for administration in each area. Dr. Banahan provided an overview report to the Board of the previous three RSV seasons in Mississippi and resultant Synagis utilization for DOM's beneficiaries. No action was required by the Board.

FDA Drug Safety Updates
Dr. Pittman reviewed FDA drug safety communications released from February 2018 – April 2018.

Additional Discussion
Dr. Noble distributed a notice from the Mississippi State Department of Health regarding the issuance of a state-wide standing order by Dr. Mary Currier, the Mississippi State Health Officer. This standing order permits pharmacists to dispense by request naloxone without a prescription from a physician or other practitioner.

Next Meeting Information:
Dr. Taylor announced the next meeting of the DUR Board will take place on September 20, 2018 at 2:00 p.m. He thanked everyone for their attendance and participation at the May 2018 DUR Board meeting.

The meeting adjourned at 3:41pm.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

PUBLIC MEETING NOTICES

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145 Jackson, MS 39201

Contact Information: Pharmacy Bureau:
Chris Yount, 601-359-5253: Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: May 31, 2018 at 2PM; Sept. 20, 2018 at 2PM; Dec. 6, 2018 at 2PM.

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.